《Science》揭新发现：神秘信号通路居然与肥胖高度相关

Core Insights - The article discusses a groundbreaking research published in Science that reveals a new signaling pathway in the brain's neurons, which plays a crucial role in appetite regulation and could lead to new anti-obesity strategies. Currently, obesity affects approximately 40% of adults in the U.S. and over 1 billion people globally [6][7]. Group 1: Research Findings - The research team, led by Dr. Zhao Zhang, discovered a previously unknown signaling pathway in the cilia of brain neurons that regulates appetite, presenting a new breakthrough for weight loss treatments [7]. - The study highlights the rapid development of weight loss medications that not only achieve lasting weight control but also show significant benefits for cardiovascular health, blood sugar balance, and management of blood pressure and cholesterol [7]. - The team utilized an Automated Meiotic Mapping (AMM) technique, which combines genetics and machine learning to efficiently locate gene mutations associated with specific phenotypes, leading to the identification of the Gpr45 gene as a key player in weight regulation [8]. Group 2: Mechanism of Action - GPR45 protein is highly expressed in hypothalamic neurons and is primarily located in primary cilia, which are crucial for appetite regulation. The study found that GPR45 acts as a transporter for the Gαs protein, activating the MC4R signaling pathway to control appetite [9]. - The absence of GPR45 results in the inability of Gαs to enter the cilia, leading to uncontrolled eating behaviors in affected mice. This suggests that enhancing GPR45 activity could provide a new therapeutic avenue for a broader range of obesity patients [9]. Group 3: Implications for Treatment - Existing medications targeting MC4R are limited to treating obesity caused by rare gene mutations and are not suitable for the wider obesity population due to potential risks from affecting other receptors [9]. - The research suggests that future drug development could focus on enhancing GPR45 activity, offering new hope for treating obesity in a more extensive patient population [9].